<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Immuno-Oncology</td>
<td>Dr. Wilson Miller</td>
</tr>
<tr>
<td>2</td>
<td>Hematology</td>
<td>Dr. John Kuruvilla</td>
</tr>
<tr>
<td>3</td>
<td>Lung Cancer</td>
<td>Dr. Normand Blais</td>
</tr>
<tr>
<td>4</td>
<td>Gastrointestinal Cancer</td>
<td>Dr. Sharlene Gill</td>
</tr>
<tr>
<td>4</td>
<td>Genitourinary Cancer</td>
<td>Dr. Sebastien Hotte</td>
</tr>
<tr>
<td>5</td>
<td>Head and Neck Cancer</td>
<td>Dr. Denis Soulières</td>
</tr>
<tr>
<td>6</td>
<td>Breast Cancer &amp; Palliative Care</td>
<td>Dr. Daniel Rayson</td>
</tr>
</tbody>
</table>
### Hematology – Dr. John Kuruvilla

**FRIDAY JUNE 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 PM - 6:00 PM</td>
<td>8000. Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).</td>
</tr>
</tbody>
</table>

**SATURDAY JUNE 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 PM - 6:00 PM</td>
<td>7000. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.</td>
</tr>
</tbody>
</table>

**SUNDAY JUNE 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45 AM - 12:45 PM</td>
<td>7503. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).</td>
</tr>
<tr>
<td>9:45 AM - 12:45 PM</td>
<td>7506. PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).</td>
</tr>
</tbody>
</table>

### Immuno-Oncology – Dr. Wilson Miller

**SATURDAY JUNE 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM - 9:30 AM</td>
<td>101. A phase Iib dose escalation study of the OX40 agonist MOX0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumours.</td>
</tr>
<tr>
<td>1:15 PM - 4:15 PM</td>
<td>3001. CheckMate 012: Safety and efficacy of first-line (IL) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC tumours.</td>
</tr>
</tbody>
</table>

**MONDAY JUNE 6**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:15 PM - 4:15 PM</td>
<td>9505. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).</td>
</tr>
<tr>
<td>1:15 PM - 4:15 PM</td>
<td>9520. Novel T cell exhaustion marker to predict monotherapy PD-1 compared to combination CTLA-4 and PD-1 response in melanoma.</td>
</tr>
</tbody>
</table>

### Lung Cancer – Dr. Normand Blais

### Gastrointestinal Cancer – Dr. Sharlene Gill

### Genitourinary Cancer – Dr. Sebastien Hotte

### Head and Neck Cancer – Dr. Denis Soulières

### Breast Cancer & Palliative Care – Dr. Daniel Rayson
Lung Cancer – Dr. Normand Blais

SATURDAY JUNE 4

3:00 PM - 4:15 PM

SUNDAY JUNE 5

8:00 AM – 11:05 AM
8503. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumour phase Ib trial: Safety, clinical activity, and PD-L1 expression.

8:00 AM – 11:05 AM
8504. CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).

8:00 AM – 11:05 AM
LBA 8505. Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).

MONDAY JUNE 6

9:45 AM – 12:45 PM
9001. Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumour tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.

9:45 AM – 12:45 PM
9002. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.

9:45 AM – 12:45 PM
9003. Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).

9:45 AM – 12:45 PM
9004. Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study.

9:45 AM – 12:45 PM
9008. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study.

1:15 PM TO 2:45 PM
9009. Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROSI+ non-small cell lung cancer (NSCLC).
Gastrointestinal Cancer – Dr. Sharlene Gill

SUNDAY JUNE 5

8:00 AM – 11:00 AM

8:00 AM – 11:00 AM
3504. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

8:00 AM – 11:00 AM
3507. CREST: Randomised phase III study of stenting as a bridge to surgery in obstructing colorectal cancer—Results of the UK ColoRectal Endoscopic Stenting Trial (CREST).

9:45AM - 11:15AM
103. Programmed death-1 blockade in mismatch repair deficient colorectal cancer.

Genitourinary Cancer – Dr. Sebastien Hotte

SUNDAY JUNE 5

8:00 AM – 11:00 AM
LBA4500. IMvigor210 cohort 1 report in Urothelial carcinoma Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.

8:00 AM – 11:00 AM
4506. Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).

MONDAY JUNE 6

8:00 AM – 11:00 AM
5001. A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12.

8:00 AM – 11:00 AM
5003. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer.

8:00 AM – 11:00 AM
5006. Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).

8:00 AM – 11:00 AM
5008. Phase III non-inferiority study of cabazitaxel (C) 20 mg/m² (C20) versus 25 mg/m² (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).

1:00 PM - 4:30 PM
4542. Sperm count in Swedish clinical stage I testicular cancer patients following modern adjuvant treatment.
SATURDAY JUNE 4

1:00 PM – 4:00 PM (POSTER SESSION)
4:45 PM - 6:00 PM (POSTER DISCUSSION SESSION)
6016. Salivary duct carcinoma: Clinical outcomes and prognostic factors in 157 patients and results of androgen deprivation therapy in recurrent disease (n=31)—Study of the Dutch head and neck society (DHNS).

SUNDAY JUNE 5

8:00 AM – 11:00 AM

6000. Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial.

8:00 AM – 11:00 AM
6001. Randomized phase III trial of induction chemotherapy (ICT) with docetaxel-cisplatin-5fluorouracil (DCF) followed by cisplatin-radiotherapy (CRT) or cetuximab-radiotherapy (CetRT) in patients (pts) with locally advanced unresectable head and neck cancer (LAUHNC). | 2016 ASCO Annual Meeting Abstracts.

8:00 AM – 11:00 AM
6008. BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

MONDAY JUNE 6

11:30 AM - 1:00 PM
6009. Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.

11:30 AM - 1:00 PM
6011. Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).

11:30 AM - 1:00 PM
6012. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.
8:00 AM TO 11:00 AM
10003. Randomized trial of early integrated palliative and oncology care.

8:00 AM - 11:30 AM
559. Analysis of tumour infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16).

1:00 PM – 4:00 PM
LBA1. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.

MONDAY JUNE 6
1:15 PM – 4:15 PM
507. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC).
Please join us for the 6th annual Canadian Hematology Conference (CHC 2016)! The Canadian Hematology Conference brings together a pan-Canadian and International faculty for a two day conference set at the Intercontinental Toronto Yorkville Hotel.

REGISTRATION IS NOW OPEN!
www.CAREeducation.ca/chc-2016